An Examination of the Anti-Cancer Properties of Plant Cannabinoids in Preclinical Models of Mesothelioma.
anti-proliferative
apoptosis
cannabidiol
cannabigerol
cannabinoids
mesothelioma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
05 Aug 2022
05 Aug 2022
Historique:
received:
24
06
2022
revised:
14
07
2022
accepted:
01
08
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
13
8
2022
Statut:
epublish
Résumé
Mesothelioma is an aggressive cancer with limited treatment options and a poor prognosis. Phytocannabinoids possess anti-tumour and palliative properties in multiple cancers, however their effects in mesothelioma are unknown. We investigated the anti-cancer effects and potential mechanisms of action for several phytocannabinoids in mesothelioma cell lines. A panel of 13 phytocannabinoids inhibited growth of human (MSTO and H2452) and rat (II-45) mesothelioma cells in vitro, and cannabidiol (CBD) and cannabigerol (CBG) were the most potent compounds. Treatment with CBD or CBG resulted in G0/G1 arrest, delayed entry into S phase and induced apoptosis. CBD and CBG also significantly reduced mesothelioma cell migration and invasion. These effects were supported by changes in the expression of genes associated with the cell cycle, proliferation, and cell movement following CBD or CBG treatment. Gene expression levels of
Identifiants
pubmed: 35954477
pii: cancers14153813
doi: 10.3390/cancers14153813
pmc: PMC9367527
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Lambert Initiative for Cannabinoid Therapeutics and the Bill Walsh Translational Cancer Research Laboratory through philanthropic donations.
ID : N/A
Organisme : Proud Family Fellowship
ID : N/A
Références
J Neuroimmune Pharmacol. 2015 Jun;10(2):255-67
pubmed: 25916739
Cell Death Dis. 2015 May 07;6:e1757
pubmed: 25950487
Mutat Res. 2012 Apr-Jun;750(2):132-140
pubmed: 22198210
Cannabis Cannabinoid Res. 2021 Apr 15;6(2):148-155
pubmed: 33912679
FASEB J. 2012 Apr;26(4):1535-48
pubmed: 22198381
Pharmaceut Med. 2022 Apr;36(2):99-129
pubmed: 35244889
Epilepsia. 2019 Nov;60(11):2224-2234
pubmed: 31625159
J Nat Prod. 2019 Nov 22;82(11):3047-3055
pubmed: 31686510
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
ACS Chem Neurosci. 2021 Jan 20;12(2):330-339
pubmed: 33395525
Cells. 2021 May 21;10(6):
pubmed: 34064197
Oncogene. 2018 Dec;37(49):6368-6382
pubmed: 30061636
Eur Respir Rev. 2015 Mar;24(135):115-31
pubmed: 25726562
Cancers (Basel). 2021 Aug 20;13(16):
pubmed: 34439349
Med J Aust. 2011 Sep 5;195(5):271-4
pubmed: 21895596
Front Immunol. 2020 May 19;11:951
pubmed: 32508832
J Vis Exp. 2015 Oct 02;(104):
pubmed: 26485154
J Med Chem. 2016 Apr 14;59(7):3183-203
pubmed: 26967507
J Cancer Res Clin Oncol. 2021 Sep;147(9):2507-2534
pubmed: 34259916
Molecules. 2020 Jun 05;25(11):
pubmed: 32517131
Oncotarget. 2016 Nov 22;7(47):77543-77557
pubmed: 27769052
Pharm Res. 2010 Oct;27(10):2162-74
pubmed: 20668920
J Exp Clin Cancer Res. 2019 Aug 13;38(1):350
pubmed: 31409387
J Thorac Oncol. 2018 Sep;13(9):1269-1283
pubmed: 29966799
Psychopharmacology (Berl). 2012 Feb;219(3):859-73
pubmed: 21796370
Thorac Cancer. 2020 Dec 1;:
pubmed: 33289348
Br J Cancer. 2009 Aug 18;101(4):691-8
pubmed: 19672268
Cannabis Cannabinoid Res. 2022 Jun;7(3):294-303
pubmed: 34182770
Sci Rep. 2014 Aug 21;4:6152
pubmed: 25141917
Cannabis Cannabinoid Res. 2021 Sep 27;:
pubmed: 34569849
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
Cell Cycle. 2020 May;19(9):961-989
pubmed: 32249682
J Clin Oncol. 2003 Jul 15;21(14):2636-44
pubmed: 12860938
BMJ Case Rep. 2021 Oct 14;14(10):
pubmed: 34649854
Eur J Pharm Biopharm. 2019 Jan;134:126-137
pubmed: 30472144
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
Breast Cancer Res Treat. 2011 Aug;129(1):37-47
pubmed: 20859676
Ann Oncol. 2020 Nov;31(11):1553-1560
pubmed: 32801017
Cells. 2021 Feb 05;10(2):
pubmed: 33562819
Cannabis Cannabinoid Res. 2022 Feb;7(1):46-57
pubmed: 33998858
BMC Bioinformatics. 2021 Sep 10;22(1):433
pubmed: 34507520
Carcinogenesis. 2014 Dec;35(12):2787-97
pubmed: 25269802
Biomolecules. 2019 Jul 25;9(8):
pubmed: 31349651
Eur J Pharmacol. 2022 May 5;922:174836
pubmed: 35306000
Br J Pharmacol. 2020 Sep;177(18):4261-4274
pubmed: 32608111
Pharmaceuticals (Basel). 2021 Nov 17;14(11):
pubmed: 34832951
Chest. 2012 Nov;142(5):1267-1273
pubmed: 22576637
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2699-704
pubmed: 18263732
Curr Oncol. 2016 Mar;23(2):S8-S14
pubmed: 27022315
Differentiation. 1988;37(2):158-71
pubmed: 2840315
Radiat Oncol. 2022 Jan 25;17(1):17
pubmed: 35073960
Molecules. 2022 Jan 13;27(2):
pubmed: 35056807
Occup Environ Med. 2017 Dec;74(12):851-858
pubmed: 28866609
Carcinogenesis. 2011 Sep;32(9):1324-32
pubmed: 21729925
Mol Cancer Ther. 2011 Jul;10(7):1161-72
pubmed: 21566064
Adv Biol Regul. 2021 Jan;79:100774
pubmed: 33422460
SAGE Open Med Case Rep. 2019 Feb 21;7:2050313X19832160
pubmed: 30815264
BMC Complement Altern Med. 2016 Sep 01;16(1):335
pubmed: 27586579
Br J Cancer. 2022 Jul;127(1):1-13
pubmed: 35277658
J Thorac Dis. 2013 Dec;5(6):E254-307
pubmed: 24416529
Arthritis Rheumatol. 2017 Nov;69(11):2193-2202
pubmed: 28804991
Front Pharmacol. 2021 Mar 03;12:637801
pubmed: 33746760
Front Pharmacol. 2016 Oct 07;7:361
pubmed: 27774065
Br J Pharmacol. 2005 Apr;144(8):1032-6
pubmed: 15700028
Biochem Pharmacol. 2010 Apr 1;79(7):955-66
pubmed: 19914218
Cancer Res. 1995 Mar 15;55(6):1227-31
pubmed: 7882313
Am J Pathol. 1987 Dec;129(3):448-62
pubmed: 2827488
Sci Rep. 2021 Jul 22;11(1):14948
pubmed: 34294753